These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 23879812

  • 21. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-α therapy.
    Pivarcsi A, Meisgen F, Xu N, Ståhle M, Sonkoly E.
    Br J Dermatol; 2013 Sep; 169(3):563-70. PubMed ID: 23600954
    [Abstract] [Full Text] [Related]

  • 22. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
    Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F.
    J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
    [Abstract] [Full Text] [Related]

  • 23. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells.
    Wehner R, Bitterlich A, Meyer N, Kloß A, Schäkel K, Bachmann M, Schmitz M.
    Int J Cancer; 2013 Mar 15; 132(6):1351-9. PubMed ID: 22907335
    [Abstract] [Full Text] [Related]

  • 24. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
    Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG.
    J Immunol; 2005 Aug 15; 175(4):2721-9. PubMed ID: 16081850
    [Abstract] [Full Text] [Related]

  • 25. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.
    Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM, Chen CS, Fu W, Gudjonsson JE, McCormick TS, Ward NL.
    J Immunol; 2013 Mar 01; 190(5):2252-62. PubMed ID: 23359500
    [Abstract] [Full Text] [Related]

  • 26. Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment.
    de Groot M, Teunissen MB, Picavet DI, de Rie MA, Bos JD.
    Exp Dermatol; 2010 Aug 01; 19(8):754-6. PubMed ID: 20482616
    [Abstract] [Full Text] [Related]

  • 27. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
    Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, Economopoulos T, Stavrianeas NG, Katsambas A.
    Clin Exp Dermatol; 2011 Dec 01; 36(8):845-50. PubMed ID: 21790728
    [Abstract] [Full Text] [Related]

  • 28. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis.
    Campanati A, Orciani M, Gorbi S, Regoli F, Di Primio R, Offidani A.
    Br J Dermatol; 2012 Jul 01; 167(1):68-76. PubMed ID: 22356229
    [Abstract] [Full Text] [Related]

  • 29. Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis.
    Bosè F, Petti L, Diani M, Moscheni C, Molteni S, Altomare A, Rossi RL, Talarico D, Fontana R, Russo V, Altomare G, Reali E.
    Am J Pathol; 2013 Aug 01; 183(2):413-21. PubMed ID: 23731727
    [Abstract] [Full Text] [Related]

  • 30. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
    Bosè F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, Caprioli F, Scavelli R, Altomare G, Geginat J, Abrignani S, Reali E.
    Clin Immunol; 2011 May 01; 139(2):164-76. PubMed ID: 21334981
    [Abstract] [Full Text] [Related]

  • 31. Mechanisms of action of etanercept in psoriasis.
    Tan JK, Aphale A, Malaviya R, Sun Y, Gottlieb AB.
    J Investig Dermatol Symp Proc; 2007 May 01; 12(1):38-45. PubMed ID: 17502868
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity.
    Baumeister SH, Hölig K, Bornhäuser M, Meurer M, Rieber EP, Schäkel K.
    Blood; 2007 Oct 15; 110(8):3078-81. PubMed ID: 17616642
    [Abstract] [Full Text] [Related]

  • 35. Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept.
    Giunta A, Babino G, Manetta S, Mazzotta A, Chimenti S, Esposito M.
    Drug Dev Res; 2014 Nov 15; 75 Suppl 1():S27-30. PubMed ID: 25381970
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C, Freundlich B.
    Eur J Dermatol; 2010 Nov 15; 20(3):323-8. PubMed ID: 20185386
    [Abstract] [Full Text] [Related]

  • 37. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C, Nasorri F, Girolomoni G, Pità Od, Cavani A.
    Br J Dermatol; 2007 Aug 15; 157(2):249-58. PubMed ID: 17489975
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
    Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB.
    J Invest Dermatol; 2005 Jun 15; 124(6):1275-83. PubMed ID: 15955104
    [Abstract] [Full Text] [Related]

  • 40. Effect of etanercept on insulin sensitivity in nine patients with psoriasis.
    Marra M, Campanati A, Testa R, Sirolla C, Bonfigli AR, Franceschi C, Marchegiani F, Offidani A.
    Int J Immunopathol Pharmacol; 2007 Jun 15; 20(4):731-6. PubMed ID: 18179745
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.